ClinicalTrials.gg
CompletedNCT00889382Updated Nov 20, 2024

A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)

A Phase 1/2 interventional study of OSI-906 and Paclitaxel in Ovarian Cancer and Solid Tumors, sponsored by Astellas Pharma Inc. Completed at 46 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-20.

Sponsored by Astellas Pharma Inc · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2014, 12 years 3 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Sep 2014.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
152
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 155 studies testing paclitaxel in Ovarian Neoplasms — 13 open to participants now, 21 under way, 6 of them phase 3. Paclitaxel · Ovarian Neoplasms.

Enrollment
29th of 143
152 · median 50
Started
2009
with 4 others
Phase 1/2
9 of 155
none open now
Registered
79th of 155
by date

Among the 155 studies testing paclitaxel in Ovarian Neoplasms, this one is the 29th largest by enrollment of the 143 interventional ones that give a count, is one of 5 that started in 2009, is one of 9 in phase 1/2, and was the 79th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

13 of the 155 studies testing paclitaxel in Ovarian Neoplasms are open now, in 9 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About paclitaxel

Paclitaxel: first FDA approval 1992 (TAXOL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 155 studies testing paclitaxel in Ovarian Neoplasms, or all of them as a file.
02

Study summary

This is a multi-center, randomized, open-label, phase 1/2 study of continuous weekly paclitaxel and escalating doses of intermittent or continuous OSI-906 in patients with recurrent/relapsed ovarian and other solid tumors.

Read the detailed description

The phase 1 dose escalation portion will establish the maximum tolerated dose (MTD) in patients with advanced solid tumors. Once the recommended phase 2 dose (RP2D) is established for both schedules, the phase 2 study will begin. Patients with relapsed/recurrent epithelial ovarian cancer will be randomized 1:1:1 to 3 treatment groups.

03

Conditions studied

  • Ovarian Cancer
  • Solid Tumors

Browse trials for

Keywords

  • Ovarian
  • IGF-1R
  • Paclitaxel
  • Ovarian Cancer
  • OSI-906
  • Solid Tumors
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed epithelial ovarian carcinoma Patients with fallopian or peritoneal cancer will also be eligible
  • Patients with any solid tumor that may be treated with weekly paclitaxel will be eligible for the phase 1 portion
  • For the phase 2 portion, patients must have elevated CA125 levels evaluable/assessable according to Gynecological Cancer Intergroup (GCIG) criteria (ie, > 70 U/mL) documented by 2 measurements at least 1 week apart
  • Patients must have radiologically confirmed progressive disease by v1.1 criteria within 6 months prior to randomization. (patients must have according to RECIST v1.1)
  • (ECOG) performance status(PS) 0 -1
  • Predicted ≥ 12 weeks
  • Patients may have had prior therapy, providing the following conditions are met:

    • Chemotherapy: Prior chemotherapy must have been completed at least 3 weeks prior to study enrollment (6 weeks for mitomycin C, nitrosoureas or high-dose carboplatin [≥ 600 mg/m²]and 4 weeks for drugs

      1. Patient should have recovered from any drug-related toxicities (with the exception of grade 1 neuropathy and or alopecia)
      2. Phase 1: While there is no limit on the number of prior regimens for patients entered into the phase 1 portion, any prior taxane therapy must have been administered on a 3 week schedule
      3. Phase 2: Patients must have received prior chemotherapy, which must have contained a platinum and a taxanes at some point. Any prior taxanes therapy must have been administered on a 3 week schedule. A maximum of 2 prior chemotherapy regimens are permitted. Patients must be radiologically confirmed by computerized tomography (CT) scan progressive disease (PD) during chemotherapy) or resistant (radiologically confirmed by CT scan PD within six months of completing chemotherapy) to their last platinum-containing chemotherapy regimen
    • Radiation: Patients may have had prior radiation therapy provided they have recovered from the acute, toxic effects of radiotherapy prior to registration/randomization. Radiated lesions cannot be chosen as the target lesions

      a. A minimum of 21 days must have elapsed between the end of radiotherapy and registration/randomization into the study unless the radiation affected less than 25% of bone marrow

    • Surgery: Previous surgery is permitted provided that adequate wound healing has occurred prior to registration/randomization
  • Fasting glucose ≤ 150 mg/dL (8.3 mmol/L)
  • Adequate hematopoietic, hepatic, and renal function defined as follows:

    • ≥ 1.5 x 10 \^9 /L and count > = 100 x 10\^9/L;
    • ≤ 1.5 x (ULN);
    • and/or ALT ≤ 2.5 x ULN or \< = 5 x ULN if patient has documented liver ; and
    • Serum creatinine ≤ 1.5 x ULN
  • Female patient must be either:

    • Of non :

      1. (defined as at least 1 year without any menses) prior to Screening, or
      2. documented surgically sterile or status post hysterectomy (at least 1 month prior to Screening)
    • Or, if of childbearing potential:

      1. must have a negative urine pregnancy test at Screening, and
      2. must use two forms of (one of which must be a barrier method) starting at Screening and throughout the study period and for 28 days [or 5 half lives, whichever is longer] after final study drug administration
  • Female patient must not be breastfeeding at Screening or during the study period and for 28 days [or 5 half lives of the study drug whichever is longer] after final study drug administration
  • Female patient must not donate ova starting at Screening and throughout the study period and for 28 days [or 5 half lives of the study drug whichever is longer] after final study drug administration
  • Patients must provide verbal and written to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Diabetes mellitus currently requiring medication (eg, insulin or oral hypoglycemics)
  • During the phase 2 portion, patients with histology of abdominal adenocarcinoma of unknown origin or a diagnosis of a borderline ovarian tumor
  • Previous or concurrent (excluding curatively treated basal or squamous cell carcinoma of the skin or cervical carcinoma in situ) unless the patient has been in remission for at least 3 years
  • History of significant cardiovascular disease unless the disease is well-controlled. Significant cardiac diseases includes second/third degree heart block; significant ischemic heart disease; poorly controlled hypertension; congestive heart failure of (NYHA) Class II or worse (slight limitation of physical activity; comfortable at rest, but ordinary physical activity results in fatigue, palpitation, or dyspnea)
  • History of cerebrovascular accident (CVA) within 6 months prior to registration/randomization or that is not stable
  • Prior therapy with an insulin-like growth factor (IGF-1R) inhibitor
  • Use of drugs that have a risk of causing prolongation within 14 days prior to Day 1 dosing
  • Known or prior to taxanes in spite of premedication or drugs containing Cremophor
  • Gastro-intestinal abnormalities, including bowel obstruction, inability to take oral medication, requirement for intravenous (IV) alimentation,active peptic ulcer or prior surgical procedures or bowel resection affecting absorption
  • Active infection or serious underlying medical condition (including any type of active seizure disorder within 12 months prior to registration/randomization) that would impair the ability of the patient to receive protocol treatment
  • History of any psychiatric condition that might impair the patient's ability to understand or to comply with the requirements of the study or to provide
  • Pregnancy or breast-feeding
  • Symptomatic that are not stable, require , are potentially life threatening, or that have required radiation within 28 days prior to registration/randomization
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to the study drug
  • History of arrhythmia (multifocal premature ventricular contractions [PVCs], bigeminy, trigeminy, ventricular tachycardia, or uncontrolled atrial fibrillation) that is symptomatic or requires treatment (≥ grade 3), left bundle branch block (LBBB), or asymptomatic sustained ventricular tachycardia are not allowed. Patients with atrial fibrillation controlled by medication are not excluded. Patients with mean QTcF interval ≥ 450 msec at screening are excluded
  • Use of drugs that have a known risk of causing Torsade de Pointes (TdP) or that that have a risk of causing QT interval prolongation within 14 days prior to Day 1 dosing are prohibited
  • Use of the potent CYP1A2 inhibitors ciprofloxacin and fluvoxamine. Other less potent CYP1A2 inhibitors/inducers are not excluded
  • Participated in any interventional clinical study or has been treated with any drugs within 30 days or 5 half lives whichever is longer, prior to the initiation of Screening or during the course of the study
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
152 participants (actual)

Study arms

  • Experimental
    Phase 1 Arm A

    Intermittent OSI-906 Once Daily (QD) on Days 1 - 3, 8 - 10, and 15 - 17 with paclitaxel on Days 1, 8, and 15 (except Treatment Period 1 (TP 1); in TP 1 OSI-906 on Days 1 - 3, 8 - 10, 15 - 17, and 22 - 24 with paclitaxel on Days 8, 15, and 22)

    Drug: OSI-906 · Drug: Paclitaxel

  • Experimental
    Phase 1 Arm B1

    Continuous OSI-906 Twice Daily (BID) (Days 1 - 21) with paclitaxel dosing on Days 1, 8, and 15;(except TP 1; in TP 1 OSI-906 on Days 1 - 3, 8 - 10, 15 - 17, and 22 - 24 with paclitaxel on Days 8, 15 and 22)

    Drug: OSI-906 · Drug: Paclitaxel

  • Experimental
    Phase 1 Arm B2

    Continuous OSI-906 BID (Days 1 - 21) with paclitaxel dosing on Days 1, 8, and 15 (except TP 1; in TP 1 OSI-906 on Days 1 - 3, 8 - 10, 5 - 17, and 22 - 24 with paclitaxel on Days 8, 15, and 22); (additional PK sampling on Days 9 or 13 0r 14 for TP 1)

    Drug: OSI-906 · Drug: Paclitaxel

  • Experimental
    Phase 1 Arm B3

    Continuous OSI-906 BID (Days 1 - 21) with paclitaxel dosing on Days 1, 8, and 15 with no separation in OSI-906 and paclitaxel dosing (except TP 1; in TP 1 continuous OSI-906 dosing 2 hours prior to the initiation of paclitaxel infusion on Day 8 only, with paclitaxel on Days 8, 15, and 22, and additional PK sampling on Day 9 or 13 or 14)

    Drug: OSI-906 · Drug: Paclitaxel

  • Experimental
    Phase 2 Arm A

    Intermittent OSI-906 QD on Days 1 - 3, 8 - 10, and 15 - 17 with paclitaxel on Days 1, 8, and 15

    Drug: OSI-906 · Drug: Paclitaxel

  • Experimental
    Phase 2 Arm B

    Continuous OSI-906 BID from Day 1 onwards with paclitaxel on Days 1, 8, and 15

    Drug: OSI-906 · Drug: Paclitaxel

  • Experimental
    Phase 2 Arm C

    Paclitaxel on Days 1, 8, and 15

    Drug: Paclitaxel

  • Experimental
    Phase 2 Arm C Roll-over

    Continuous OSI-906 BID from Day 1 onwards

    Drug: OSI-906

Interventions

06

What researchers measure

Primary outcomes

  1. Determine Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)

    Primary outcome measure for Phase 1 portion

    Time frame: 28 days

  2. Progression Free Survival (PFS)

    Primary outcome measure for the Phase 2 portion; The time from the date of randomization until date of radiographic disease progression per RECIST v1.1 or until death due to any cause

    Time frame: 36 months

Secondary outcomes

  1. Objective Response Rate (ORR)

    The proportion of patients with a confirmed response of Complete Response (CR) or Partial Response (PR) per RECEIST v1.1

    Time frame: 36 months

  2. Cancer Antigen 125 (CA125) Response Rate

    Response Rate is defined as at least 50% reduction in serum CA-125 levels from pretreatment levels; Response rate is the proportion of patients with a CA-125 response among evaluable patients

    Time frame: 36 months

  3. Duration of Response (DOR)

    The time from the date of the first documented radiographic response (CR/PR) to first documented radiographic progression or death due to underlying cancer

    Time frame: 36 months

  4. Duration of CA-125 Response (CA-125 DOR)

    The time from the date of the first documented CA-125 response to the date of CA-125 progression

    Time frame: 36 months

  5. Overall Survival (OS)

    The time from the date of randomization until the documented date of death

    Time frame: 36 months

  6. Safety assessed via physician exam, vital signs, clinical laboratory tests, electrocardiograms (ECG), and adverse events

    Time frame: 36 months

07

Study locations

46 sites
  • Mayo Clinic
    Scottsdale, Arizona 85259, United States
  • Department of Obstetrics and Gynecology, University of California, Irvine
    Orange, California 92868, United States
  • Horizon Oncology Center
    Lafayette, Indiana 47906, United States
  • Ochsner Clinic Foundation
    New Orleans, Louisiana 70121, United States
  • Morristown Memorial Hospital
    Morristown, New Jersey 07960, United States
  • Blumenthal Cancer Center - Main
    Charlotte, North Carolina 28204, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104, United States
  • WestMead Hospital
    WestMead, New South Wales 2145, Australia
  • Mater Adult Hospital
    South Brisbane, Queensland 4101, Australia
  • Royal Adelaide Hospital
    North Terrace, South Australia 5000, Australia
  • Launceston General Hospital
    Launceston, Tasmania 7250, Australia
  • Frankston Hospital
    Frankston, Victoria 3199, Australia
  • Border Medical Oncology
    Wodonga, Victoria 3690, Australia
  • St. John of God Hospital, Bunbury
    Bunbury, Western Australia 6230, Australia
  • Sir Charles Gairdner Hospital
    Perth, Western Australia 6009, Australia
  • St. John of Gog Hospital, Subiaco
    Subiaco, Western Australia 6008, Australia
  • Juravinski Cancer Center
    Hamilton, Ontario L8V 5C2, Canada
  • Princess Margaret Hospital
    Toronto, Ontario M5G 2M9, Canada
  • McGill University
    Montreal, Quebec H3T 1E2, Canada
  • University Hospital Hradec Kralove
    Kralove, 50005, Czechia
  • University Hospital Ostrava
    Ostrava- Poruba, 70852, Czechia
  • General University Hospital, Department of Obstetrics and Gynecology
    Prague, 212000, Czechia
  • Universitaria di Bologna Policlinico
    Bologna, 40138, Italy
  • Ospedale di Carpi, AUSL di Modena
    Carpi, 91012, Italy
  • Instituto Europeo di Oncologia
    Milan, 20141, Italy
  • Oncology IDI- IRCSS
    Roma, 67100, Italy
  • III Oddzial Onkologii Ginekologicznej
    Lublin, 20-090, Poland
  • Oddzial Radioterapii
    Poznan, 61 866, Poland
  • Klinika Onkologii AM w Poznaniu
    Poznan, 61-878, Poland
  • Institutul Oncologic Prof. Dr. Ion. Chiricuta Sectia de Oncologie Medicala
    Cluj Napoca, 400015, Romania
  • Institutul Oncologic Prof. Dr. Ion. Chiricuta Sectia Radiologie
    Cluj Napoca, 400015, Romania
  • Oncology Medical Centre SCM
    Iasi, 700106, Romania
  • Clinical Caunty Hospital Mures
    Mures, 540072, Romania
  • Central Clinical Hospital
    Moscow, 129128, Russian Federation
  • Moscow City Oncology Hospital
    Moscow, 143423, Russian Federation
  • State Institution Medical Radiology Scientific Center
    Obninsk, 249036, Russian Federation
  • Sity Clinical Oncology
    St. Petersburg, 198255, Russian Federation
  • Ospedale San Giovanni
    Bellinzona, CH-6500, Switzerland
  • Drug Development Unit Royal Mardsen NHS Foundation Trust
    Sutton, Surrey SM2 5PT, United Kingdom
  • Royal Marsden Hospital
    London, SW3 6JJ, United Kingdom
  • University College Hospital
    London, WC1E 6BT, United Kingdom
  • The Christie NHS Foundation Trust
    Manchester, M20 4BX, United Kingdom
  • Mount Vernon Cancer Center
    Northwood, HA62RN, United Kingdom
  • Churchill Hospital
    Oxford, OX37LI, United Kingdom
  • Christie NHS Foundation Trust
    Withington, M20 4BX, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.

Access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.

Data sharing details ↗ · www.clinicaltrials.astellas.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2009 to primary completion in Aug 2014, 59 months.

Of 116 industry-sponsored phase 1/2 interventional studies under Ovarian Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 88. This study's 59 months is close to that.

Counting every sponsor, half of 173 studies reached it within 65 months; a quarter within 44 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2009
First posted
Apr 28, 2009
StartActual
Aug 5, 2009
Primary completionActual
Aug 1, 2014
CompletionActual
Aug 25, 2014
Results delay requested
Sep 22, 2014
Last update
Nov 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00889382
Responsible party
Sponsor
First posted
Apr 28, 2009
Start date
Aug 5, 2009
Primary completion
Aug 1, 2014
Completion
Aug 25, 2014
Last update
Nov 20, 2024

Study contacts

Principal Investigator - Czech Republic
principal investigator · General Faculty Hospital, Charles University
Medical Director
study director · Astellas Pharma Global Development
Principal Investigator - Italy
principal investigator · Instituto Europeo de Oncologia

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Linsitinib · Paclitaxel

Start the discussion